Company: INDP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001641172-25-023490
Chunk: 47

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 47
---
 part of this prospectus from the date of the filing of such reports and documents.

We will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates. You should direct oral or written requests by one of the following methods. Attention: Investor Relations, Indaptus Therapeutics, Inc., Three Columbus Circle, 15th Floor New York, NY 10019, (646) 427-2727. You may also access these documents, free of charge on the SEC’s website at www.sec.gov or on the “Investors” page of our website at https://indaptusrx.com. The information found on our website, or that may be accessed by links on our website, is not part of this prospectus. We have included our website address solely as an inactive textual reference. Investors should not rely on any such information in deciding whether to purchase our securities.

| 35 |

<div align='center'>PART II
INFORMATION NOT REQUIRED IN PROSPECTUS</div>

Item 14. Other Expenses of Issuance and Distribution

The following table sets forth an estimate of the fees and expenses, other than the underwriting discounts and commissions, payable by us in connection with the issuance and distribution of the securities being registered. All the amounts shown are estimates.

| SEC Registration Fee         |     | $ | 30,620 |
| FINRA Fee                    |     | $ | 30,500 |
| Accounting Fees and Expenses |     | $ |      * |
| Legal Fees and Expenses      |     | $ |      * |
| Printing Fees and Expenses   |     | $ |      * |

| * | These fees are calculated                                                                                                                 
 based on the securities offered and the number of issuances and accordingly cannot be estimated at this time. An estimate of the          
 aggregate expenses in connection with the sale and distribution of securities being offered will be included in the applicable prospectus 
 supplement.                                                                                                                               |

Item 15. Indemnification of Directors and Officers.

Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses including attorneys’ fees, judgments, fines and amounts paid in settlement in connection with various